Thus, there are tremendous research efforts in constructing the mutant IL-2 with tumor targeting that increases binding to CD8+ T cells and reduces affinity to Tregs, which can alter antitumor response in tumor microenvironment and activate tumor-specific CTLs, thus leading to significantly improved anti-tumor responses (De Luca et al.2017; Hartimath et al.2018; Zhu et al.2015). This evidence concerns the gene CD8A and neoplasm.